Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker ...

Currently, a multidistrict litigation against Pfizer (NYSE: PFE) is underway on behalf of women who claim to have developed meningiomas after receiving four or more consecutive injections of ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition ...

Sanofi is paying up to US $1.6 billion for Vicebio, taking UQ’s Molecular Clamp vaccine tech global in Australia’s biggest university IP exit.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Sanofi’s $1.76 billion acquisition of Vicebio delivers a windfall for the University of Queensland — and highlighted a ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

In July 2025, Sanofi announced that its SAR446597 therapy received fast track designation from the US FDA for treating geographic atrophy due to age-related macular degeneration, highlighting its ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...